2 results about "Cell-mediated cytotoxicity" patented technology

Compositions and methods for treating general persistent viral infections, particularly long COVID, are described. The compositions comprise T cells, antigen presenting cells (APCs), and optionally NK cells derived from a patient's whole blood. The APCs are genetically engineered to comprise nucleic acids encoding antigenic peptide sequences for MHC-complexed cell surface expression, where further exposure to an IL-15 agonist and patient T cells can produce activation and expansion of virus-educated T cells for readministration to the patient, thereby targeting cells harboring the virus to T cell-mediated cytotoxicity.

To provide more effective immunotherapy against individual immune checkpoint inhibitor molecules such as PD-1.SOLUTION: The present invention provides a humanized bispecific antibody that simultaneously detects and neutralizes both CHI3L1 and the immune checkpoint inhibitor PD-1, wherein these antibodies exhibit enhanced synergistic cytotoxic effects compared to the effects of individual CHI3L1 and PD-1 antibodies, alone or in combination. A pharmaceutical composition comprising the bispecific antibody, and a therapeutic agent for cancer comprising the bispecific antibody, are also provided.SELECTED DRAWING: None